Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 25Terminated 8Active not recruiting 6Recruiting 5Unknown 3Withdrawn 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 34Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Squamous Cell Carcinoma of Head and Neck 23Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 13Uterine Cervical Neoplasms 12Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Lung Diseases 5Adenocarcinoma of Lung 5Thoracic Neoplasms 4

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Carboplatin × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California, Davis

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02393157 2025-08-08

O-ICE

New York Medical College

Phase 2 Recruiting
25 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med Inc

Phase 3 Recruiting
416 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡